Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2415
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration ; volume:20 ; number:1 ; day:10 ; month:7 ; year:2020 ; pages:1-7 ; date:12.2020
BMC ophthalmology ; 20, Heft 1 (10.7.2020), 1-7, 12.2020
- Creator
-
Itagaki, Kanako
Sekiryu, Tetsuju
Kasai, Akihito
Sugano, Yukinori
Ogasawara, Masashi
Saito, Masaaki
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12886-020-01542-6
- URN
-
urn:nbn:de:101:1-2020090820090960196494
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Itagaki, Kanako
- Sekiryu, Tetsuju
- Kasai, Akihito
- Sugano, Yukinori
- Ogasawara, Masashi
- Saito, Masaaki
- SpringerLink (Online service)
Other Objects (12)
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis
Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis
Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis